<DOC>
	<DOCNO>NCT02148796</DOCNO>
	<brief_summary>The primary objective study evaluate Broncho-Vaxom® give high risk infant 10 day , monthly , two consecutive year increase time occurrence first episode wheeze low respiratory tract illness ( WLRI ) third observation year therapy</brief_summary>
	<brief_title>Oral Bacterial Extract Prevention Wheezing Lower Respiratory Tract Illness</brief_title>
	<detailed_description>This 36 month parallel arm , double-blind , placebo-controlled trial prevention WLRI third fifth year life ( 30 54 mo inclusive ) young child ( 6-18 month old ) increase risk asthma . The trial divide 2 period . During initial treatment period ( first second year study ) participant receive Broncho-Vaxom® ( 3.5 mg ) placebo ten day month two consecutive year . This period allow observation key secondary outcome participant receive therapy . A rolling enrollment strategy use anticipate two year enrollment period whole study . The second period ( third year study ) one year observation time occurrence first WLRI episode ( primary outcome ) study drug along secondary outcome note . During treatment observation period , participant manage study physician use rescue algorithm apply PEAK ( Prevention Early Asthma Kids ) trial commensurate NAEPP-EPR ( National Asthma Education Prevention Program - Expert Panel Report ) III guideline .</detailed_description>
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Broncho-Vaxom</mesh_term>
	<criteria>Adequate completion inform consent process write documentation . The participant 's legally acceptable representative must provide appropriate write informed consent . Assent form use due age participant population ; however , procedure later study participant old , age appropriate assent obtain , required local IRB . Age : 618 month age inclusive randomization mean 5 17 month age inclusive entry one month runin period . At least half enrol child 6 12 month age randomization . Participants meet least one follow criterion , associate increase risk wheeze respiratory illness asthma : ) Parental history asthma b ) Physiciandiagnosed atopic dermatitis participant . Participants may either male female . Participants least one parent/guardian communicate study staff allow assessment study outcome . All study material use parent/guardian make available English Spanish . The child 's parent/guardian must work direct contact telephone . Participants may two prior WLRI episode . Participants may SWLRI episode . Participants may physician 's diagnosis asthma . Participants may systemic illness ( allergy ) include ( limited ) recurrent seizure , chronic gastroesophageal reflux ( GER ) require medical treatment , major congenital anomaly , physical intellectual delay , cerebral palsy , chest surgery , tuberculosis chronic infection , primary secondary immunodeficiency , gastrointestinal malformation disease cardiac disorder ( except hemodynamically insignificant ASD , VSD benign heart murmur ) . Participants may bear early 36 week gestation . Participants may receive oxygen 5 day neonatal period , receive mechanical ventilation exclusion ventilation anesthesia minor surgical procedure . Participants may significant neurodevelopmental delay . Participants may 3rd percentile weight . Participants may chronic lung disease ; e.g . chronic lung disease prematurity ( CLDP ) cystic fibrosis . Participants may history lifethreatening respiratory illness require intubation mechanical ventilation . The participant 's family may expect relocate study area within 3 year initiation study . Participants may receive inhaled systemic corticosteroid respiratory relate illness ever , condition month prior randomization . Participants may ever receive immunotherapy . Participants may ever receive i.v . gammaglobulins systemic immunosuppressant . Participants may receive probiotic ( Lactobacilli Bifidobacteria ) medicinal form ; ( i.e . include food ) , regularly 4 month 6 &lt; 12 mo age group 6 month 12 18 month group prior enrollment . Participant known sensitivity study product ingredient administer . Participant previously randomize study . Participants fail runin randomize may study participation terminate reenrolled second runin period . Participant currently enrol complete investigational device drug study &lt; 30 day prior screen , receive investigational agent ( ) . Participant significant medical condition ( ) , anticipate need major surgery study , kind disorder may associate increase risk participant , may interfere study assessment , outcome , ability provide write informed consent comply study procedure , Investigator 's opinion . The one month runin period use evaluate adherence study drug administration electronic communication . At randomization participant must continue meet enrolment criterion also demonstrate 80 % adherence placebo treatment period ; i.e . 8 10 day a75 % response rate weekly mobile phone text query ; i.e . 3 4 weekly text query . Ongoing infection ( organ system ) time randomization . This include infection adequately treat . Unable unlikely complete study assessment study intervention pose undue risk patient opinion Investigator . Families speak English and/or Spanish .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wheezing</keyword>
	<keyword>Lower respiratory tract illness</keyword>
	<keyword>Asthma</keyword>
	<keyword>Atopy</keyword>
</DOC>